Well-controlled oral anticoagulation lowers the risk of ischaemic stroke in patients with atrial fibrillation; however, conflicting evidence exists on its benefits and risks in patients with end-stage renal disease. Shah and colleagues examined this question in a large cohort of patients on dialysis who were diagnosed with atrial fibrillation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Winkelmayer, W. C., Patrick, A. R., Liu, J., Brookhart, M. A. & Setoguchi, S. The increasing prevalence of atrial fibrillation among hemodialysis patients. J. Am. Soc. Nephrol. 22, 349–357 (2011).
Shah, M. et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation http://dx.doi.org/10.1161/CIRCULATIONAHA.113.004777.
Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223–2233 (2009).
Wizemann, V. et al. Atrial fibrillation in hemodialysis patients: clinical features and associations with anticoagulant therapy. Kidney Int. 77, 1098–1106 (2010).
Winkelmayer, W. C., Liu, J., Setoguchi, S. & Choudhry, N. K. Effectiveness and safety of warfarin initiation in older hemodialysis patients with incident atrial fibrillation. Clin. J. Am. Soc. Nephrol. 6, 2662–2668 (2011).
Olesen, J. B. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367, 625–635 (2012).
Ray, W. A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915–920 (2003).
Seliger, S. L., Gillen, D. L., Longstreth, W. T. Jr, Kestenbaum, B. & Stehman-Breen, C. O. Elevated risk of stroke among patients with end-stage renal disease. Kidney Int. 64, 603–609 (2003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W.C.W has served as an advisor or consultant to Amgen, Keryx Biopharmaceuticals, Medgenics, Medtronic and Mitsubishi Tanabe Pharma. He serves as an associate editor (nephrology) for JAMA and a co-editor of the American Journal of Kidney Diseases.
Rights and permissions
About this article
Cite this article
Winkelmayer, W. Still unresolved: warfarin in ESRD with atrial fibrillation. Nat Rev Nephrol 10, 244–245 (2014). https://doi.org/10.1038/nrneph.2014.48
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2014.48
